论文部分内容阅读
绝大多数处于慢性粒细胞白血病(CML)慢性期的病人,经过大剂量放化疗,接受HLA相合的同胞供者未做处理的骨髓,进行骨髓移植(BMT)治疗后,将不会再出现复发,与此完全相反,大量经同样放化疗后,而接受体外去淋巴细胞处理的骨髓移植病例,经观察在移植后2至3年出现复发,这些资料表明:单纯放化疗几乎不能清除白血病克隆,而供者的淋巴细胞具有重要的抗白血病作用,并被称为移植物抗白血病(GVL)作用,以下有关的观察结果,近一步证明了在CML BMT后GVL所起的作用:①急、慢
The vast majority of patients in the chronic phase of chronic myelogenous leukemia (CML) undergo large doses of radiochemotherapy and bone marrow that has not been treated by HLA matched sibling donors will not relapse after bone marrow transplantation (BMT) treatment In contrast to this, a large number of bone marrow transplant recipients who have undergone in vitro lymphocyte treatment after the same chemoradiation have been observed to have recurrence within 2 to 3 years after transplantation. These data indicate that simple radiotherapy and chemotherapy can hardly eliminate leukemia clones. The donor’s lymphocytes have an important anti-leukemia effect and are referred to as graft-versus-leukemia (GVL) effects. The following observations further demonstrate the role of GVL after CML BMT: 1 Urgent and slow